Based on our previous work of p-eIF4E as prognosticmarker independent of tumor heterogeneity, we have extended the international patent for EB1 - thefirst in class allosteric inhibitor of the eIF4E phosphorylating kinases MNK1/2to Europe, Japan and USA. We are currently exploring the clinical application indifferent cancers. Following on the discovery of the role of ITGB3 in cell-cellcommunication via extracellular vesicles in breast cancer metastasis, we arecurrently screening for inhibitors to translate these findings to the clinic. Wepublished a novel in-vitro model of metastasis where RNA-Seq identified putativegenes and specific pathways vulnerable for targeting during this process.Following our discovery that the gap junction protein Cx43 regulates the formationtunneling nanotubes (TNTs), which regulate malignancy and therapy-resistance, weinitiated an AECC grant to identify therapeutic novel peptidesto inhibit these cell-cell communication networks in cancer.

Group Leader
Santiago Ramon y Cajal Agüeras

Principal Investigator (PI)
Trond Aasen, Cleofé Romagosa Pérez-Portabell

Researchers
Josep Castellví Vives, Domínguez Oronoz, Elena Antima Martinez Saez, Vicente Peg Camara, Maria Teresa Salcedo Allende, Irene Sansano Valero, Javier Hernandez Losa, Marta Sese Faustino, Stefan Hümmer, Konstantin Slobodnyuk

PhD Students
Nikaoly Ciriaco Cortés, Jordi Temprana Salvador, Marta Cano Galietero, Elena Muro Blanc

Lab Technicians
Ximena Garcia Torres, Teresa Moline Marimon, Maria Rosa Somoza Lopez de Haro, Maria Jose Munoz, Milena Riaño Rodriguez

68

PUBLICATIONS

402

IMPACT FACTOR

5.91

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Vargas-Accarino E, Herrera-Montávez C, Ramón Y Cajal S, Aasen T.
Spontaneous Cell Detachment and Reattachment in Cancer Cell Lines: An In Vitro Model of Metastasis and Malignancy.
Int J Mol Sci. 2021 May 6;22(9):4929
DOI: doi: 10.3390/ijms22094929
IF: 5.924

Hümmer S, Borao S, Guerra-Moreno A, Cozzuto L, Hidalgo E, Ayté J
Cross talk between the upstream exon-intron junction and Prp2 facilitates splicing of non-consensus introns
Cell Rep. 2021 Oct 26;37(4):109893
DOI: doi: 10.1016/j.celrep.2021.109893
IF: 9.423

Aasen T
Connexins, Innexins, and Pannexins: From Biology to Clinical Targets
Biomolecules. 2021 Jan 25;11(2):155
DOI: doi: 10.3390/biom11020155
IF: 4.879

Olaya-C M, Garrido M, Franco JA, Rodríguez JL, Vargas MJ, Aula-Olivar A, Quintero L, Ramón Y Cajal S
Spiral Arteries in Second Trimester of Pregnancy: When Is It Possible to Define Expected Physiological Remodeling as Abnormal?
Reprod Sci. 2021 Apr;28(4):1185-1193
DOI: doi: 10.1007/s43032-020-00403-3
IF: 3.06

Peg V, López-García MÁ, Comerma L, Peiró G, García-Caballero T, López ÁC, Suárez-Gauthier A, Ruiz I, Rojo F
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
Future Oncol. 2021 Apr;17(10):1209-1218
DOI: doi: 10.2217/fon-2020-1100
IF: 3.404

La vía de los factores MNK/eIF4E como nuevas dianas terapéutica en cáncer: un modelo para incrementar la sensibilidad a quimioterapia e inmunoterapia
Principal Investigator: Santiago Ramon y Cajal
Agency: Instituto de Salud Carlos III
Funding: 123,420 €
Period: 2021-2023

Exploring a novel interplay between gap junctions and tunnelling nanotubes in cancer
Principal Investigator: Trond Aasen
Agency: Fundación Científica de la Asociación Española Contra el Cáncer
Funding: 20,000€
Period: 2020-2022

Efectos bifásicos y formas truncadas de la Cx43 en cáncer de mama: aplicaciones pronósticas y terapéuticas
Principal Investigator: Trond Aasen
Agency: Instituto de Salud Carlos III
Funding: 92,565€
Period: 2017-2021

INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY METHODS AND THERAPEUTIC COMBINATIONS
Priority Number: PCT/EP2020/069459 (WO2021005183)
Priority Date: 09/07/2020
Applicants: 47% VHIR/ 50% IQS /3% CIBERONC

Oncology

Research Areas